A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPG1860
Latest Information Update: 27 Apr 2022
At a glance
- Drugs HPG 1860 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Hepagene Therapeutics
Most Recent Events
- 23 Aug 2021 According to a Hepagene Therapeutics media release, detailed results from this study will be presented at upcoming AASLD international liver conference.
- 23 Aug 2021 Results presented in the Hepagene Therapeutics Media Release.
- 24 Oct 2019 New trial record